Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd commences an Equity Buyback for CNY 15 million worth of its shares, under the authorization approved on April 15, 2024.
June 05, 2024 at 05:14 am
Share
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) commences share repurchases on June 4, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on April 15, 2024. As per the mandate, the company is authorized to repurchase its A shares for a total of CNY 15 million. The shares will be purchased at a price not exceeding CNY 13.36 per share. The repurchased shares will be cancelled thereby reducing the registered capital. The program will be funded from company's own funds. The program will be valid for 12 months from the date of the shareholder's meeting.
On May 14, 2024, the company amended its share repurchase program. The shares will be repurchased at a price not exceeding CNY 13.32 per share.
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd is a China-based company mainly engaged in the distribution and retail business of drugs, biological products, medical devices and other products. The Company is also engaged in reproductive hospital business. The pharmaceutical distribution business includes pure sales mode and allocation mode, mainly engaged in anti-tumor drugs, immunomodulatory drugs, cardiovascular and cerebrovascular drugs, respiratory drugs, antiviral drugs and other new and special drugs. The pharmaceutical retail business is mainly engaged in professional pharmacies, focusing on the sales of prescription drugs, mainly including Special Service pharmacy business and direct to patient (DTP) pharmacy business. The reproductive hospital business is mainly engaged in the diagnosis and treatment of gynecological and urological diseases.
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd commences an Equity Buyback for CNY 15 million worth of its shares, under the authorization approved on April 15, 2024.
HUNAN DAJIAWEIKANG PHARMACEUTICAL INDUSTRY CO.,LTD 
